BALVERSA™ (erdafitinib) for Healthcare Professionals
It’s time to take a different direction With THE FIRST treatment for metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations that has progressed after first-line platinum-based chemotherapy1
BALVERSA™ is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has
susceptible fibroblast growth factor receptor (FGFR) 3 or FGFR2 genetic alterations and
progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA™.
This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.